These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29566967)

  • 1. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout.
    Tedeschi SK; Hayashi K; Zhang Y; Choi H; Solomon DH
    Ann Rheum Dis; 2024 Sep; 83(10):1375-1380. PubMed ID: 38724073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare.
    Tai V; Gow P; Stewart S; Satpanich P; Li C; Abhishek A; Dalbeth N
    Semin Arthritis Rheum; 2024 Apr; 65():152367. PubMed ID: 38215627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements.
    Stamp LK; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    J Rheumatol; 2018 Mar; 45(3):419-424. PubMed ID: 29247147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
    Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
    Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
    Stewart S; Tallon A; Taylor WJ; Gaffo A; Dalbeth N
    Semin Arthritis Rheum; 2020 Apr; 50(2):303-313. PubMed ID: 31796212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study.
    Steelandt A; Hittinger A; Kanagaratnam L; Kazes I; Clavel P; Bolko L; Rieu P; Salmon JH
    BMC Nephrol; 2024 Aug; 25(1):266. PubMed ID: 39164615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
    Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
    Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
    Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
    Morillon MB; Stamp L; Taylor W; Fransen J; Dalbeth N; Singh JA; Christensen R; Lassere M
    BMJ Open; 2016 Sep; 6(9):e012026. PubMed ID: 27650765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
    Stamp LK; Chapman P; Frampton C; Duffull SB; Drake J; Zhang Y; Neogi T
    Rheumatology (Oxford); 2020 Sep; 59(9):2374-2380. PubMed ID: 31891407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
    Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
    Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Topless R; Noorbaloochi S; Merriman TR; Singh JA
    Semin Arthritis Rheum; 2022 Oct; 56():152057. PubMed ID: 35835008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis.
    Kampe RT; Nielsen SM; Hotea I; van Durme C; Christensen R; Boonen A
    Semin Arthritis Rheum; 2022 Oct; 56():152049. PubMed ID: 35728446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.